Pneumocystis carinii pneumonia during maintenance treatment of childhood acute lymphoblastic leukemia

2001 ◽  
Vol 37 (1) ◽  
pp. 20-23 ◽  
Author(s):  
Anja Poulsen ◽  
Ann Kathrin Demeny ◽  
Charlotte Bang Plum ◽  
Kim Gjerum Nielsen ◽  
Kjeld Schmiegelow
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Pneumocystis Carinii Pneumonia ◽  
Maintenance Treatment ◽  
Lymphoblastic Leukemia ◽  
Pneumocystis Carinii ◽  
Childhood Acute Lymphoblastic Leukemia

Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92

Blood ◽  
2003 ◽  
Vol 102 (8) ◽  
pp. 2736-2740 ◽  
Author(s):  
Dörthe O. Harms ◽  
Ulrich Göbel ◽  
Hans J. Spaar ◽  
Ulrike B. Graubner ◽  
Norbert Jorch ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Maintenance Treatment ◽  
Lymphoblastic Leukemia ◽  
Clinical Effectiveness ◽  
Multicenter Trial ◽  
Observation Time ◽  
Childhood Acute Lymphoblastic Leukemia ◽  
Cooperative Study Group ◽  
Childhood All

Abstract The German cooperative study group for childhood acute lymphoblastic leukemia (COALL-92) was designed to examine the clinical effectiveness of thioguanine (TG) versus mercaptopurine (MP) in maintenance treatment of childhood acute lymphoblastic leukemia (ALL) in a randomized multicenter trial. TG and MP are prodrugs and have to be converted intracellularly to 6-thioguanine nucleotides (TGNs) for cytostatic activity. TG is converted into TGN in fewer steps and has been shown to be more cytotoxic in equimolar doses in vitro compared with 6-MP. Therefore, a higher effectiveness of TG in maintenance treatment was postulated. Of 521 patients enrolled into the protocol, 474 were randomized to receive either MP or TG during maintenance therapy in a daily oral dose. After a median observation time of 6.6 years, the probability of event-free survival was 79% ± 3% for the MP group (238 children) and 78% ± 3% in the TG group (236 patients). In spite of TGN levels, exceeding those of the MP group 7 times, treatment with TG did not improve the outcome but was more complicated to handle due to a specific toxicity profile of prolonged myelosuppression with marked thrombocytopenia. Therefore, MP should remain the preferred drug for maintenance treatment of ALL, unless other studies demonstrate superiority of TG in larger trials or selected patient groups.

Genetic characterization of high hyperdiploidy in childhood acute lymphoblastic leukemia

2009 ◽  
Vol 221 (03) ◽  
Author(s):  
R Vagkopoulou ◽  
C Eckert ◽  
U Ungethüm ◽  
G Körner ◽  
M Stanulla ◽  
...  
Keyword(s):  
Acute Lymphoblastic Leukemia ◽  
Genetic Characterization ◽  
Lymphoblastic Leukemia ◽  
Childhood Acute Lymphoblastic Leukemia
Sign in / Sign up

Export Citation Format

Share Document